Patient Death in Pfizer's Hympavzi Trial Raises Safety Questions for Hemophilia Treatment
Pfizer investigates death of hemophilia patient in Hympavzi trial after thrombotic stroke. Company says no expected safety impact for approved use.
/ 1662 items
#XY↓
Reviva's Schizophrenia Drug Faces Major Setback: FDA Demands Second Phase 3 Trial
FDA rejects Reviva's NDA plans for brilaroxazine, requiring additional Phase 3 trial. Launch delayed until at least 2026+, contingent on securing funding for the study.
JonesResearch Starts Coverage on Atai Beckley & Mind Medicine with Buy Ratings
JonesResearch gives Buy ratings to Atai Beckley and Mind Medicine, highlighting potential in psychedelic drug development for depression and anxiety.
Oppenheimer Starts Coverage on Aardvark Therapeutics with Strong Rating
Oppenheimer analyst gives Aardvark Therapeutics an Outperform rating with $35 price target, highlighting rare and common obesity drug programs and a key Phase 3 trial.
Oppenheimer Starts Coverage on Spruce Biosciences with Bullish Outlook
Oppenheimer initiates coverage of Spruce Biosciences with an Outperform rating, citing strong FDA signals, accelerated approval potential, and possible acquisition interest from BioMarin.
Cantor Fitzgerald Starts Coverage on ArriVent Biopharma with Strong Upside
Cantor Fitzgerald initiates coverage on ArriVent Biopharma with an Overweight rating, highlighting strong Phase 3 potential and significant upside.